This page has been optimized for print.

GET SWIMSUIT READY FASTER AND EASIER THAN EVER BEFORE WITH NEW LIFESCULPT LASER TREATMENT

LifeSculpt is minimally-invasive and offers a faster recovery time than traditional liposuction

Burlington, MA, June 24, 2009 /PRNewswire/ — Palomar Medical Technologies, Inc., a leading researcher and developer for cosmetic treatments, announced today the nationwide availability of the LifeSculpt body sculpting laser procedure. LifeSculpt features the SlimLipo laser body sculpting technology, which selectively targets and "melts" fat in a minimally-invasive way. As a minimally-invasive procedure, LifeSculpt provides a faster recovery time as compared to traditional liposuction with little to no bruising, allowing patients to return to daily activities quickly.

LifeSculpt is the optimal choice for people who are already healthy, have tried diet and exercise and still have a problem area. The unique technology utilized in the LifeSculpt procedure allows access to even the most difficult-to-reach areas such as the fat under the chin, backs, arms, and inner thighs.

LifeSculpt allows physicians to remove excess fat and tighten the skin through laser-assisted lipolysis and subsequent fat removal. A recent limited study published in US Dermatology, by Robert Weiss, M.D., Director of the Maryland Laser, Skin, and Vein Institute; found that all subjects agreed that the LifeSculpt procedure significantly improved the appearance of the treated areas of their bodies. In addition, the study found that 100 percent of patients saw an improvement in skin's smoothness and tightness within three months after treatment.

"This study proved what I'd been experiencing in my own practice; LifeSculpt offers superior results, better than any other type of fat reduction and fat removal method on the market," said Dr. Weiss.

"During the recovery period after the LifeSculpt procedure, skin tightening may occur as new collagen is laid down in the layers of the skin. Improvement in skin firmness can continue for up to six months after the procedure; this is particularly gratifying to patients who have experienced significant skin laxity that is often associated with age and weight loss," noted Brooke Seckel, M.D., plastic surgeon at Boston Plastic Surgery Associates, Concord MA

"There is an emerging demand for this kind of option among consumers - people want stellar results, but do not want to have to take time out of their busy schedules to achieve those results," noted Richard Bankowski, Field Clinical Director for Palomar Medical Technologies, Inc..

Please visit www.LifeSculpt.com to find more information on LifeSculpt such as "before" and "after" photos and a find-a-provider functionality.

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

For more information on Palomar and its products, visit Palomar's website at www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations section of the website.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current expectations, plans, intentions, beliefs or predictions. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2008 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.